Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

This study has been completed.
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: September 1, 2009
Last updated: April 10, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2013
  Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):